All News

Eraglusib with gemcitabine and nab-paclitaxel achieved statistical significance in the first-line treatment of metastatic pancreatic ductal adenocarcinoma.

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for some with bladder cancer.

Dr. Kara Kelly discusses some of the most common challenges faced by adolescent and young adult patients with lymphoma.

Biomarker testing is vital for all patients with lung cancer, especially younger individuals who have higher rates of actionable mutations.

Dr. Daniel J. Boffa shared how cancer care teams support patients in quitting smoking and how new data may guide improvements in high-smoking U.S. regions.

The first trial site has been initiated in the pivotal phase 3 OVATION 3 study which will investigate IMNN-001 for newly diagnosed advanced ovarian cancer.

I’m 22 years out from breast cancer and forever grateful for the nurses who gave me not just treatment but friendship, laughter and a community of hope.

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian cancer with KRAS mutations.

Danyelza is now a recommended treatment in NCCN guidelines for relapsed or refractory high-risk neuroblastoma, a type of brain cancer.

This is a joint nomination by Camille Moses and Dr. Estelamari Rodriguez.

Lung cancer remains the leading cause of cancer-related deaths in the U.S.

LCI has appointed Neal Ready, MD, PhD, as its first Chief Scientific Officer.

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop radiation pneumonitis.

Lung Cancer Initiative proudly participated in the GO2 Voices Summit held March 9–11, 2025, in Washington, DC.

Dr. Daniel J. Boffa discusses the link between smoking cessation and increase in survival for people who are active smokers and diagnosed with cancer.

Eric Z. cared for my sister and mentored me with compassion, wisdom and unwavering presence — shaping my path in nursing and life.

Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma

Treatment with an Enhertu regimen significantly improved pathologic complete responses for patients with high-risk HER2-positive early-stage breast cancer.

After 30 years with breast cancer, I urge others to pause, reflect and choose care based on long-term wellbeing, not fear or pressure.

I would like to nominate Ashley Tullio, RN, for the Extraordinary Healer Award for Oncology Nursing.

Dr. Armine Smith discusses the importance of personalized therapeutic approaches for the treatment of urologic cancers, such as bladder or kidney cancer.

She wore a variety of bright sneakers and occasionally did a cha-cha-cha in them. Her laughter was contagious. Patients smiled. The other nurses smiled.

Treatment with givinostat has received fast track designation from the United States Food and Drug Administration for patients with polycythemia vera.

The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer and neuroendocrine carcinomas.

Dr. Cathy Eng discusses data that led to the FDA approval of Braftovi and Erbitux plus chemo for metastatic colorectal cancer with a BRAF V600E mutation.

Everyone knows someone who has been affected by cancer.

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment plan.

Dr. Shirley D'Sa discusses the importance of catching peripheral neuropathy in patients with Waldenström macroglobulinemia early on and how to treat it.